Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling

Bibliography

• Kola I, Lanhis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 2004;3:711-16
   PubMed Web of Science ®Google Scholar
• Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the slone survey. JAMA 2002;287:337-44
   PubMed Web of Science ®Google Scholar
• Lee JY, Lee SY, Oh SJ, et al. Assessment of drug–drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chem Biol Interact 2012;198:49-56
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. editor. In drug–drug interactions. Drugs and the pharmaceutical sciences, 116. Marcel Dekker; New York: 2002
   Google Scholar
• Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
   PubMed Web of Science ®Google Scholar
• Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. Am J Cardio Drugs 2004;4:281-97
   PubMedGoogle Scholar
• FDA. Guidance for industry–drug interaction studies–study design, data analysis, implications for dosing, and labeling recommendations (draft guidance). 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
   Google Scholar
• EMA. Guideline on the investigation of drug interactions (final). 2013. Available from: http://www.ema.europa u/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
   Google Scholar
• Grimm SW, Einolf HJ, Hall SD, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009;37:1355-70
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Chen L, Fahmi OA, et al. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharm Ther 2014;95:179-88
   PubMed Web of Science ®Google Scholar
• Vieira ML, Kirby B, Ragueneau-Majlessi I, et al. Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin Pharm Ther 2014;95:189-98
   PubMed Web of Science ®Google Scholar
• Riley RJ, Grime K, Weaver R. Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 2007;3:51-66
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007;8:449-62
   PubMed Web of Science ®Google Scholar
• Ortiz de Montellano PR, Correia MA. Inhibition of cytochrome P450 enzymes. In. Ortiz de Montellano PR, editors. Cytochrome P450: structure, mechanism, and biochemistry. 2nd edition. Plenum Press; New York: 1995. p. 305-64
   Google Scholar
• Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential–toward a consensus. Pharm Res 2001;18:1071-80
   PubMedGoogle Scholar
• Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharm 2004;57:473-86
   PubMed Web of Science ®Google Scholar
• Zimmerlin A, Trunzer M, Faller B. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos 2011;6:1039-46
   Google Scholar
• Zhou S, Yung CS, Cher GB, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug–drug interaction risk assessment. Xenobiotica 2007;37:1225-56
   PubMed Web of Science ®Google Scholar
• Silverman RB. In: Contemporary Enzyme Kinetics and Mechanism. Purich DL editor, Mechanism-based enzyme inactivation. Academic Press; San Diego, CA: 1996. p. 291-335
   Google Scholar
• Kalgutkar AS, Obach RS, Maurer TS. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure–activity relationships and relationship to clinical drug–drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab 2007;8:407-47
   PubMed Web of Science ®Google Scholar
• Riley RJ. The potential pharmacological and toxicological impact of P450 screening. Curr Op Drug Disc Dev 2001;1:45-54
   Google Scholar
• Smith DA, Dickins M, Fahmi OA, et al. The time to move cytochrome P450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos 2007;35:697-8
   PubMed Web of Science ®Google Scholar
• Badolo L, Jensen B, Säll C, et al. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture. Xenobiotica 2014;3:1-11
   Google Scholar
• Guengerich FP, Shimada T, Iwasaki M, et al. Activation of carcinogens by human liver cytochromes P-450. Basic Life Sci 1990;53:381-96
   PubMedGoogle Scholar
• Lin JH. CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharm Res 2006;23:1089-116
   PubMed Web of Science ®Google Scholar
• Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampicin. Hepatology 1996;24:796-801
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Zhang G, Kenny JR, et al. Evaluation of multiple in vitro systems for assessment of CYP3A4 induction in drug discovery: human hepatocytes, pregnane x receptor reporter gene, and Fa2N-4 and HepaRG cells. Drug Metab Dispos 2009;37:1259-68
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23
   PubMed Web of Science ®Google Scholar
• Olinga P, Elferink MG, Draaisma AL, et al. Coordinated induction of drug transporters and Phase I and II metabolism in human liver slices. Eur J Pharm Sci 2008;33:380-9
   PubMed Web of Science ®Google Scholar
• Wei P, Zhang J, Dowhan DH, et al. Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response. Pharmacogenomics J 2002;2:117-26
   PubMedGoogle Scholar
• Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro–in vivo correlations. Xenobiotica 2007;37:1196-224
   PubMed Web of Science ®Google Scholar
• Fahmi OA, Kish M, Boldt S, et al. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane x receptor-activated induction of drug-metabolizing enzymes. Drug Metab Dispos 2010;38:1605-11
   PubMed Web of Science ®Google Scholar
• Ripp SL, Mills JB, Fahmi OA, et al. Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos 2006;34:1742-8
   PubMed Web of Science ®Google Scholar
• Kenny JR, Chen L, McGinnity DF, et al. Efficient assessment of the utility of immortalized Fa2N-4 cells for cytochrome P450 (CYP) induction studies using multiplex quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and substrate cassette methodologies. Xenobiotica 2008;38:1500-17
   PubMed Web of Science ®Google Scholar
• Goodwin B, Hodgson E, Liddle C. The orphan human pregnane x receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharm 1999;56:1329-39
   PubMed Web of Science ®Google Scholar
• Kanebratt KP, Andersson TB. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metab Dispos 2008;36:137-45
   PubMed Web of Science ®Google Scholar
• Mukadam S, Tay S, Tran D, et al. Evaluation of time-dependent cytochrome p450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach. Drug Met Lett 2012;6:43-53
   PubMedGoogle Scholar
• Li P, Chuang L, Balani SK, et al. A refined cytochrome P450 IC50 shift assay for reliably identifying CYP3A4 time-dependent inhibitors. Drug Metab Dispos 2011;39:1054-7
   PubMed Web of Science ®Google Scholar
• Zientek M, Stoner C, Ayscue R, et al. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 2010;3:664-76
   Google Scholar
• McGinnity DF, Berry AJ, Kenny JR, et al. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab Dispos 2006;34:1291-300
   PubMed Web of Science ®Google Scholar
• Li AP. Human hepatocytes; Isolation, cryopreservation and applications in drug development. Chem Biol Interact 2007;168:16-29
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma. Drug Metab Dispos 2011;39:591-602
   PubMed Web of Science ®Google Scholar
• Mao J, Mohutsky MA, Harrelson JP, et al. Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions. Drug Metab Dispos 2012;40:706-16
   PubMed Web of Science ®Google Scholar
• Li AP, Doshi U. Higher throughput human hepatocyte assays for the evaluation of time-dependent inhibition of CYP3A4. Drug Met Lett 2011;5:183-91
   PubMedGoogle Scholar
• Yates P, Eng H, Di L, et al. Statistical methods for analysis of time-dependent inhibition of cytochrome P450 enzymes. Drug Metab Dispos 2012;40:2289-96
   PubMed Web of Science ®Google Scholar
• Nagar S, Jones JP, Korzekwa K. A numerical method for analysis of in vitro time-dependent inhibition data. Part 1. Theoretical considerations. Drug Metab Dispos 2014;42:1575-86
   PubMed Web of Science ®Google Scholar
• Korzekwa K, Tweedie D, Argikar UA, et al. A numerical method for analysis of in vitro time-dependent inhibition data. Part 2. application to experimental data. Drug Metab Dispos 2014;42:1587-95
   PubMed Web of Science ®Google Scholar
• Rodriguez-Antona C, Jover R, Gomez-Lechon MJ, et al. Quantitative RT-PCR measurement of human cytochrome P450s: application to drug induction studies. Arch Biochem Biophys 2000;376:109-16
   PubMed Web of Science ®Google Scholar
• El-Sankary W, Gibson GG, Ayrton A, et al. Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 2001;29:1499-504
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Fleming HE, Khetani SR. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014;32:504-13
   PubMed Web of Science ®Google Scholar
• Greenhough S, Medine CN, Hay DC. Pluripotent stem cell derived hepatocyte like cells and their potential in toxicity screening. Toxicology 2010;278:250-5
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23
   PubMed Web of Science ®Google Scholar
• Raucy J, Warfe L, Yueh MF, et al. A cell-based reposter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharm Exp Ther 2002;303:412-23
   PubMed Web of Science ®Google Scholar
• Trubetskoy O, Marks B, Zielinski T, et al. A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J 2005;2:E6-13
   Google Scholar
• Shukla S, Sakamuru S, Huang R, et al. Identification of clinically used drugs that activate pregnane x receptors. Drug Metab Dispos 2011;39:151-9
   PubMed Web of Science ®Google Scholar
• Ghanbari F, Rowland-Yeo K, Bloomer JC, et al. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr Drug Metab 2006;7:315-34
   PubMed Web of Science ®Google Scholar
• Grime KH, Bird J, Ferguson D, et al. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. Eur J Pharm Sci 2009;36:175-91
   PubMed Web of Science ®Google Scholar
• Filppula AM, Neuvonen PJ, Backman JT. In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors. Drug Metab Dispos 2014;7:1202-9
   Google Scholar
• Fahmi OA, Hurst S, Plowchalk D, et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 2009;37:1658-66
   PubMed Web of Science ®Google Scholar
• Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000;28:1031-7
   PubMed Web of Science ®Google Scholar
• Maurel P. The use of adult human hepatocytes in primary culture and other in vitro systems to investigate drug metabolism in man. Adv Drug Deliv Rev 1996;22:105-32
   Web of Science ®Google Scholar
• Pichard L, Fabre I, Daujat M, et al. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin a oxidase activity in primary cultures of human hepatocytes. Mol Pharm 1992;41:1047-55
   PubMed Web of Science ®Google Scholar
• Yang J, Liao M, Shou M, et al. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008;9:384-94
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharm Ther 2003;74:121-9
   PubMed Web of Science ®Google Scholar
• Lilja JJ, Kivisto KT, Backman JT, et al. Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol 2000;56:411-15
   PubMed Web of Science ®Google Scholar
• Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharm 1995;49:61-7
   PubMed Web of Science ®Google Scholar
• Takanaga H, Ohnishi A, Matsuo H, et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharm 2000;49:49-58
   PubMed Web of Science ®Google Scholar
• Galetin A, Burt H, Gibbons L, et al. Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-75
   PubMed Web of Science ®Google Scholar
• Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66
   PubMed Web of Science ®Google Scholar
• Ito K, Ogihara K, Kanamitsu S, et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 2003;31:945-54
   PubMed Web of Science ®Google Scholar
• Rowland Yeo K, Jamei M, Yang J, et al. Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut – the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 2010;39:298-309
   PubMed Web of Science ®Google Scholar
• Zhang X, Quinney SK, Gorski JC, et al. Semi-physiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite. Drug Metab Dispos 2009;37:1587-97
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug–drug interactions. Drug Metab Dispos 2007;35:246-55
   PubMed Web of Science ®Google Scholar
• Wang YH. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug–drug interactions for mechanism-based CYP3A inhibitors. Drug Metab Dispos 2010;38:1094-104
   PubMed Web of Science ®Google Scholar
• Rowland-Yeo K, Walsky RL, Jamei M, et al. Prediction of time-dependent CYP3A4 drug–drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci 2011;43:160-73
   PubMed Web of Science ®Google Scholar
• Galetin A, Gertz M, Houston JB. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Exp Op Drug Metab Toxicol 2008;4:909-22
   PubMed Web of Science ®Google Scholar
• Galetin A, Gertz M, Houston JB. Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 2010;25:28-47
   PubMed Web of Science ®Google Scholar
• Galetin A, Hinton LK, Burt H, et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007;8:685-93
   PubMed Web of Science ®Google Scholar
• Kenny JR, Mukadam S, Zhang C, et al. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 2012;7:1960-76
   Google Scholar
• Fahmi OA, Boldt S, Kish M, et al. Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes. Drug Metab Dispos 2008;36:1971-4
   PubMed Web of Science ®Google Scholar
• Grime K, Ferguson DD, Riley RJ. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches. Curr Drug Metab 2010;11:870-85
   PubMed Web of Science ®Google Scholar
• Zhang JG, Ho T, Callendrello AL, et al. Evaluation of calibration curve–based approaches to predict clinical inducers and noninducers of CYP3A4 with plated human hepatocytes. Drug Metab Dispos 2014;42:1379-91
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Feng K, et al. The Simcyp population-based ADME simulator. Exp Op Drug Metab Toxicol 2009;5:211-23
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 2010;49:239-58
   PubMed Web of Science ®Google Scholar
• Heikkinen AT, Baneyx G, Caruso A, et al. Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™. Eur J Pharm Sci 2012;47:375-86
   PubMed Web of Science ®Google Scholar
• Siccardi M, Marzolini C, Seden K, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet 2013;52:583-92
   PubMed Web of Science ®Google Scholar
• Varma MV, Lin J, Bi YA, et al. Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 2013;41:966-74
   PubMed Web of Science ®Google Scholar
• Yamashita F, Sasa Y, Yoshida S, et al. Modelling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS One 2013;8:e70330
   PubMed Web of Science ®Google Scholar
• Han B, Mao J, Chien JY, et al. Optimization of drug-drug interaction study design: comparison of minimal physiologically based pharmacokinetic models on prediction of CYP3A inhibition by ketoconazole. Drug Metab Dispos 2013;41:1329-38
   PubMed Web of Science ®Google Scholar
• Varma MV, Bi YA, Kimoto E, et al. Quantitative prediction of transporter- and enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1b1 substrates using a mechanistic net-effect model. J Pharm Exp Ther 2014;351:214-23
   PubMed Web of Science ®Google Scholar